|
Gilead's agent is the holy grail of HCV treatment..
(Preview)
Commentary: Gilead's agent is the holy grail of HCV treatmentBarring any safety bombshells, a prolific pipeline of direct-acting anti-viral agents (DAAs) is due to start issuing forth options that, when combined, will permit all-oral, interferon-free treatment. By making future HCV treatme...
|
Cinnamon Girl
|
0
|
770
|
|
|
|
|
7977 Sofosbuvir Priority Review
(Preview)
From Vicky: Designation for Sofosbuvir for the Treatment of Hepatitis C FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 7, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company's New Drug Appl...
|
JIme
|
1
|
769
|
|
|
|
|
June 2013 HCV Advocate newsletter
(Preview)
newsletter...http://www.hcvadvocate.org/news/newsLetter/2013/advocate0613.html
|
Cinnamon Girl
|
0
|
697
|
|
|
|
|
Scotland`s Bold Approach to Diagnosing and Treating Active Drug Users
(Preview)
As Hepatitis C Spreads, Scotland Steps InJournal...http://online.wsj.com/article/SB10001424127887323466204578384760850698712.html
|
Cinnamon Girl
|
7
|
1192
|
|
|
|
|
INCIVOŽ (telaprevir) Receives European Commission Approval for Twice Daily Dosing
(Preview)
Friday, May 31, 2013INCIVOŽ (telaprevir) Receives European Commission Approval for Twice Daily Dosing for Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) -INCIVOŽ triple therapy now offers a twice daily HCV treatment regimen which should improve patient adherence -Janssen Infecti...
|
Cinnamon Girl
|
5
|
2827
|
|
|
|
|
'War on drugs' fuelling the hepatitis C epidemic among people who inject drugs..new report
(Preview)
'War on drugs' fuelling the hepatitis C epidemic among people who inject drugsThe global war on drugs has had a disastrous impact on the hepatitis C epidemic, a new report from the Global Commission on Drug Policy shows. The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C E...
|
Cinnamon Girl
|
2
|
796
|
|
|
|
|
Earlier Sustained Virologic Response End Points for Regulatory Approval
(Preview)
Earlier Sustained Virologic Response End Points for Regulatory Approval Abstract - Background & AimsTrials of therapies for chronic hepatitis C have used detection of hepatitis C virus (HCV) at week 24 of follow-up (sustained virologic response [SVR] 24) as a primary end point. However, th...
|
Cinnamon Girl
|
0
|
715
|
|
|
|
|
European Medicines Agency Validates Gileads Marketing Application for Sofosbuvir
(Preview)
European Medicines Agency Validates Gilead`s Marketing Application for Sofosbuvir for the Treatment of Hepatitis COnce-Daily Sofosbuvir will Receive an Accelerated Assessment by EMA - Designation Granted to New Medicines of Major Public Health Interest.May. 21, 2013-- Gilead Sciences, In...
|
Cinnamon Girl
|
3
|
855
|
|
|
|
|
Result of AbbVie Aviator Study followed through 48 weeks post treatment
(Preview)
http://natap.org/2013/DDW/DDW_05.htm
|
garfield
|
1
|
954
|
|
|
|
|
Hepatitis C and Dietary Supplements: What the Science Says
(Preview)
Hepatitis C and Dietary Supplements: What the Science Saysthought...http://hcvadvocate.blogspot.ca/2013/05/hepatitis-c-and-dietary-supplements.html.
|
Cinnamon Girl
|
2
|
874
|
|
|
|
|
Movement for global access to hepatitis C treatment building momentum
(Preview)
Movement for global access to hepatitis C treatment building momentumAccess to hepatitis C treatment in low- and middle-income countries is being restricted by the high cost of interferon and a lack of commitment to treating the disease, leading to a growing gap between the prospects of patients...
|
Cinnamon Girl
|
3
|
862
|
|
|
|
|
Gilead announces 3rd phase 3 trial of all oral sofosbuvir and ledipasvir combo, ION-3
(Preview)
Gilead announces 3rd phase 3 trial of fixed dose oral pillMay 2 2013 - Gilead Sciences today announced plans to initiate a third Phase 3 clinical trial of the fixed-dose combination tablet of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C virus (HCV) infection. The study, calle...
|
Cinnamon Girl
|
2
|
1405
|
|
|
|
|
Compassionate access to new hepatitis C drugs an "emergency" for European patients
(Preview)
Compassionate access to new hepatitis C drugs an "emergency" for European patients European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the 48th In...
|
Cinnamon Girl
|
3
|
1074
|
|
|
|
|
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1
(Preview)
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C RARITAN, N.J., May 13, 2013 /PRNewswire/ -- Janssen Research & Development announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to th...
|
Cinnamon Girl
|
4
|
1289
|
|
|
|
|
Future of hep C services and patient care at risk in UK due to NHS reforms..new report
(Preview)
Future of hepatitis C services and patient care at risk due to changing NHS New report suggests innovative service design could help change current state of hepatitis in the UK A new report, supported by leading hepatitis C patient groups, highlights the poor state of UK hepatitis C services compar...
|
Cinnamon Girl
|
7
|
1040
|
|
|
|
|
AbbVie's Investigational DAA Regimen Receives Breakthrough Therapy Designation from US FDA
(Preview)
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration - Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development -May 6, 2013, NORTH CHICAGO, AbbVie today announced that its investi...
|
Cinnamon Girl
|
0
|
735
|
|
|
|
|
May 2013 HCV Advocate Newsletter
(Preview)
May 2013 HCV Advocate Newsletterhttp://www.hcvadvocate.org/news/newsLetter/2013/advocate0513.htmlPrintable pdf format...http://www.hcvadvocate.org/news/NewsUpdates_pdf/Advocate%202013/advocate0513.pdf
|
Cinnamon Girl
|
0
|
791
|
|
|
|
|
News from EASL 2013
(Preview)
The new oral regimens seem to be doing well in further reports from EASL this week. Gilead looks like it will deliver to market in 2013 and be particularly effective for Genotypes 2 and 3. AbbVie reported impressive results Genotype I. 24 weeks post treatment the "cure" rate was 96%! The re...
|
Freshhope
|
9
|
1374
|
|
|
|
|
Info: New name... `HCV News`
(Preview)
Hi everyone,We`ve changed the name of this section to `HCV News` (from `News and Events`). Please could you post all the news articles you`d like to share here in this section from now on, including new drug info and updates.Many thanks from the admin team.... that`s Malcolm (mallani), Tim (hrsetr...
|
Cinnamon Girl
|
0
|
4734
|
|
|
|
|
Gilead news for Ledipasvir/sofosbuvir
(Preview)
http://www.gilead.com/news/press-releases/2013/5/gilead-reports-interim-data-from-phase-2-lonestar-study
|
gsx1250fa
|
0
|
903
|
|
|
|
|
website news
(Preview)
http://news.yahoo.com/abbvie-hepatitis-c-drugs-knock-virus-eight-weeks-100555214--finance.html A friend just sent this to me
|
onabugeisha
|
2
|
726
|
|
|
|
|
Merck announces agreement with BMS for Phase II all-oral trial of MK-5172 and Daclatasvir, for gen 1
(Preview)
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C WHITEHOUSE STATION, N.J.. 22nd April, 2013 - Merck today announced it has entered into a non-exclus...
|
Cinnamon Girl
|
0
|
752
|
|
|
|
|
Miravirsen
(Preview)
http://singularityhub.com/2013/04/17/rna-based-drug-offers-new-hope-to-hepatiti...
|
Zlikster
|
0
|
1048
|
|
|
|
|
Benitec Selects University of California, San Diego, as a Site for Phase I/II Clinical Trial of TT‐034
(Preview)
Benitec Selects University of California, San Diego, as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections SYDNEY, April 15, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of Ca...
|
Cinnamon Girl
|
0
|
771
|
|
|
|
|
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
(Preview)
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCVAll-Oral Trial to Evaluate the Safety and Efficacy of a 12-Week Regimen of Sovaprevir, ACH-3102 and Ribavirin for Genotype 1 Treatment-Naive HCV PatientsNEW HAVEN, Conn., April 16, 2013 (GLOBE NEWS...
|
Cinnamon Girl
|
1
|
746
|
|
|
|
|
FDA Approves FibroScan
(Preview)
The FDA Approves FibroScan for Noninvasive Liver Diagnosis. http://hepatitiscnewdrugs.blogspot.com/2013/04/fda-approves-fibroscan-for-noninvasive.html
|
Biggyb
|
6
|
1322
|
|
|
|
|
Roche and Ascletis announce collaboration to develop danoprevir in China
(Preview)
Basel, Switzerland and Shanghai, China - 15 April 2013Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis CRoche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche`s investigationa...
|
Cinnamon Girl
|
0
|
768
|
|
|
|
|
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir
(Preview)
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C -- Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 8, 20...
|
Cinnamon Girl
|
0
|
864
|
|
|
|
|
Vertex announces 2 All-Oral Phase 2 studies with BMS of VX-135 in Combination with Daclatasvir
(Preview)
Friday, April 5, 2013 Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C -Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 an...
|
Cinnamon Girl
|
0
|
733
|
|
|
|
|
Advances in Hep C Treatment (video) from Conference on Retroviruses and Opportunistic Infections (CROI 2013)
(Preview)
In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), in March 2013, in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Mark from Weill Cornell Medical C...
|
Cinnamon Girl
|
0
|
1255
|
|
|
